or Try an Advanced Search...

    ETF Components for PSIL - AdvisorShares Psychedelics ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    MNMD B -7.51 10.82
    ATAI B 17.52 5.83
    CMPS F 3.07 5.79
    GHRS C 1.34 5.45
    ALKS B -0.56 5.29
    SAGE F -5.03 4.82
    ITCI B -4.80 4.59
    RLMD F -4.75 4.48

    Represented by ETF Holdings

    Keywords: Biopharmaceutical Entheogens Mental Health Psychoactive Drugs Depressive Disorder Drug Development Drugs Hyperactivity Disorder Major Depressive Disorder N Dimethyltryptamine Neurochemistry Neuroscience Psychiatric And Neurological Disorders Psychiatry Schizophrenia Treatment Resistant Depression Adjunctive Therapy Aging Associated Diseases Alcohol Alzheimer's Disease
    Industries: Biotechnology Drug Manufacturers - Specialty & Generic Medical Care Facilities

    Recent News for AdvisorShares Psychedelics ETF & its Holdings

    Date Stock Title
    Nov 15 ATAI RFK and the 'MAHA Trade': Vaccine makers down, psychedelic shares up
    Nov 15 CMPS RFK and the 'MAHA Trade': Vaccine makers down, psychedelic shares up
    Nov 14 GHRS GH Research GAAP EPS of -$0.23 beats by $0.02
    Nov 14 CMPS Compass Pathways to participate in Stifel 2024 Healthcare Conference
    Nov 14 RLMD Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease
    Nov 14 MNMD Mind Medicine (MindMed) Inc.'s (NASDAQ:MNMD) market cap touched US$601m last week, benefiting both retail investors who own 41% as well as institutions
    Nov 14 GHRS GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates
    Nov 13 ATAI Atai Q3 Report: Strong Cash Position, Clinical Pipeline Growth
    Nov 13 ATAI ATAI Life Sciences GAAP EPS of -$0.16 in-line
    Nov 13 ATAI atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
    Nov 13 MNMD MindMed to Participate in Upcoming Investor Conferences
    Nov 11 ATAI Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer
    Nov 11 RLMD Weekly Roundup on the Cannabis Sector & Psychedelic Sector 11-11-2024
    Nov 10 MNMD Mind Medicine: No News = Good News
    Nov 10 RLMD Relmada Therapeutics, Inc. (RLMD) Q3 2024 Earnings Call Transcript
    Nov 10 GHRS We Think GH Research (NASDAQ:GHRS) Can Afford To Drive Business Growth
    AdvisorShares Trust - AdvisorShares Psychedelics ETF is an exchange traded fund launched and managed by AdvisorShares Investments, LLC. The fund invests in public equity markets of global region. It invests directly and through derivatives in stocks of companies operating across healthcare, pharmaceuticals, biotechnology and life sciences companies focused on plant-based psychedelic medicines as well as other companies with business activities in the psychedelics industry sectors. The fund uses derivatives such as swaps to create its portfolio. It invests in growth and value stocks of companies across diversified market capitalization. The investment seeks long-term capital appreciation. AdvisorShares Trust - AdvisorShares Psychedelics ETF is domiciled in the United States.
    Exchange Traded Funds Biotechnology Pharmaceutical Advisorshares
    Back to the Main PSIL Page...